Chlamydia Test in Australia

What a chlamydia test is

A chlamydia test is a nucleic acid amplification test that looks directly for the DNA or RNA of Chlamydia trachomatis in a urine sample or a swab, rather than looking for antibodies.

Chlamydia trachomatis is a bacterium that lives inside human cells and infects the urethra, cervix, rectum, throat and, less commonly, the eyes. It is the most frequently notified sexually transmissible infection in Australia, with tens of thousands of diagnoses recorded each year and the highest notification rates in people aged 15 to 29.

The defining clinical feature is silence. The majority of infections cause no symptoms at all — commonly cited figures are around 70% of infections in women and around 50% in men. People who do have symptoms may notice discharge, burning on passing urine, bleeding between periods or after sex, pelvic or testicular pain, or rectal discomfort. Because most infections announce nothing, testing in Australia is driven by risk and by routine screening recommendations rather than by how a person feels on any given day.

The Australian standard method is NAAT — nucleic acid amplification testing. It amplifies bacterial genetic material to a detectable level and is far more sensitive than the older culture and antigen methods it has replaced. It works on non-invasive samples: a first-catch urine sample is standard for people with a penis, while a self-collected vaginal swab is the preferred and best-performing sample for people with a vagina — it outperforms urine in this group, and performs equivalently to a clinician-collected swab, which is why self-collection is now routine rather than a compromise.

Sampling site matters and is easy to get wrong. A urine or vaginal sample does not detect an infection confined to the rectum or throat, which is why Australian sexual health guidance recommends testing at each exposed site rather than defaulting to a single genital sample. If you have had receptive anal or oral sex, a rectal or throat swab should be included in the request.

Serology — an antibody blood test — is not used to diagnose current genital chlamydia in routine practice. Antibodies persist long after an infection has cleared and cannot reliably distinguish a past, resolved infection from a current one, so it has no role in a standard screening or diagnostic pathway.

Why chlamydia testing matters

Chlamydia is tested for because it is common, usually silent, curable with prescribed antibiotics, and capable of causing serious reproductive complications if left undetected.

Untreated chlamydia can ascend from the cervix to the upper genital tract and cause pelvic inflammatory disease, which is associated with chronic pelvic pain, ectopic pregnancy and tubal-factor infertility. In people with a penis, complications include epididymo-orchitis and, less commonly, reactive arthritis. In pregnancy, chlamydia can be transmitted to the baby during birth, causing neonatal conjunctivitis or pneumonia — which is why it is specifically screened for in higher-risk antenatal care.

Because the infection is silent in most people, these complications develop in people who had no clinical reason to suspect anything was wrong. That is the entire rationale for routine, risk-based screening rather than waiting for symptoms to prompt testing.

Australian sexual health guidance recommends at least annual chlamydia testing for sexually active people aged 15 to 29, more frequent testing for men who have sex with men and for people with multiple or new partners, testing at each exposed anatomical site rather than a single default sample, and testing as part of antenatal care in higher-risk groups. Retesting around three months after a positive result is also recommended, because reinfection from an untreated partner is common and is functionally indistinguishable from treatment failure without a repeat test.

• Annual testing for sexually active people aged 15–29.
• Testing with any new sexual partner, or after unprotected sex with a partner of unknown status.
• Site-specific testing where there has been receptive anal or oral sex.
• Testing when a partner has been diagnosed with chlamydia or another STI.
• Testing before and during pregnancy where risk factors are present.
• Retesting approximately three months after treatment for a previous positive result.

What a positive result means

A positive (detected) result means Chlamydia trachomatis genetic material was found in that sample, indicating current infection at that site — a curable condition treated with prescribed antibiotics.

The first thing to know is that chlamydia is curable. Australian treatment guidelines recommend a specific antibiotic course, which is prescription-only and must be obtained from a doctor, a sexual health clinic or, in some jurisdictions, a specialist nurse-led service. FORM does not prescribe or supply medicines of any kind; a positive result should be taken promptly to your GP or a sexual health service so treatment can begin without delay.

Three things generally follow a positive result. First, treatment for you, taken exactly as prescribed by your doctor. Second, partner notification — current and recent sexual partners, generally covering the preceding six months, need testing and treatment themselves, and every Australian state and territory runs confidential partner-notification services that can contact partners anonymously on your behalf if you would rather not do it yourself. Third, avoiding sex, including with condoms, for seven days after treatment starts and until all partners have also been treated, to avoid the very common pattern of reinfecting each other back and forth.

Chlamydia is a notifiable condition throughout Australia. The diagnosing laboratory reports it to the relevant state or territory health department for public-health surveillance purposes. This is a routine, de-identified process used for population monitoring and outbreak tracking; it is not shared with employers, insurers, or anyone outside the public-health system.

A retest at approximately three months is recommended after treatment — not primarily to confirm cure, which is not usually needed for the standard first-line treatment, but to detect reinfection, which is common when a partner was not treated at the same time. A specific test of cure, taken a few weeks after treatment rather than immediately, is recommended in pregnancy and for rectal infection, where cure rates with standard treatment are less reliable.

A positive result is not a reflection of anything other than an exposure to a very common bacterium. It carries no bearing on fertility once treated promptly, and the great majority of people treated early have no lasting effects at all.

What a negative result means

A negative (not detected) result means no chlamydia genetic material was found in that sample at that site — reliable only if enough time has passed since the exposure you are asking about.

The key concept is the window period. It takes time after exposure for the bacterial load to reach a level the test can reliably detect. Australian sexual health services generally advise testing at least two weeks after a possible exposure, and repeating at around six weeks if the initial test was earlier or the exposure was considered high-risk. A negative test taken two days after a possible exposure tells you very little, because the organism simply may not have amplified to a detectable level yet.

The second limitation is anatomical. A negative urine result does not exclude rectal or throat infection, because NAAT only detects the organism where the sample was taken. If you have had receptive anal or oral sex, the corresponding site must be swabbed separately to be genuinely covered by the negative result.

The third limitation is scope. A chlamydia test only tests for chlamydia. A full Australian sexual health screen usually includes gonorrhoea (typically run on the same NAAT sample at no extra collection effort), syphilis serology, HIV, and hepatitis B and C where indicated by risk factors. If you are testing because of a specific risk event rather than routine annual screening, it is worth discussing the full panel with your GP or a sexual health clinic rather than relying on chlamydia alone.

A negative result with ongoing symptoms should still be followed up with a doctor rather than treated as reassurance to stop investigating. Urethritis, cervicitis and pelvic pain have other infectious and non-infectious causes, including gonorrhoea, Mycoplasma genitalium and trichomonas, and those need separate clinical assessment and, where appropriate, separate testing.

How Australian laboratories report chlamydia results

Chlamydia NAAT results are qualitative — reported as detected or not detected — with no numeric reference range, and accompanied by the sample site tested.

Which tests go with a chlamydia test

Chlamydia is one part of a sexual health picture. These are the tests most often run alongside it, and the reproductive-health tests people ask about in the same conversation.

• H. pylori test — an unrelated but similarly straightforward infection test people often ask about alongside STI screening.
• Semen analysis — relevant where a past infection or current symptoms raise questions about male fertility.
• Male fertility test — reproductive hormones alongside semen analysis for a fuller picture.
• Fertility blood tests — overview — for anyone whose STI history is part of a broader fertility conversation.
• Build your own Australian panel — combine chlamydia testing with other tests in a single collection.
• Browse all Australian pathology tests — see the full FORM AU test menu.

What affects a chlamydia test result

Test timing relative to exposure, the sample site chosen, recent antibiotic use, and menstrual bleeding can all change whether a chlamydia NAAT result is reliable.

Timing relative to exposure is the single biggest factor. Testing too soon after a possible exposure — inside the roughly two-week window period — can produce a false negative simply because the bacterial load has not yet reached a detectable level, regardless of how sensitive the assay is. If your exposure was recent and high-risk, an early negative result should be treated as provisional and repeated at around six weeks.

Sample site is the second major factor. Chlamydia can infect the urethra or cervix, the rectum, and the throat independently of one another, and a NAAT result only speaks to the site actually sampled. Testing only urine after receptive anal sex, for example, can produce a true negative for the urethra that says nothing about a genuinely infected rectum.

Recent antibiotic use — for this or any other infection — can suppress the bacterial load below the detection threshold without necessarily curing the infection, producing a falsely reassuring negative. If you have taken any antibiotics in the preceding few weeks, mention this on your pathology request so timing can be adjusted.

For people who menstruate, testing during menstruation is not a contraindication for a vaginal swab, but some clinicians prefer to avoid heavy bleeding days for sample quality; a self-collected vaginal swab remains reliable outside of very heavy flow.

Illness, hydration and how long urine has been held before a first-catch sample can all affect urine-based testing specifically — holding urine for at least one to two hours beforehand, and collecting the very first part of the stream rather than a midstream sample, meaningfully improves detection because that is where the highest concentration of urethral cells and organism is found.

Finally, false positives are rare with modern NAAT assays but are not impossible; a genuinely surprising positive result — for example with no plausible exposure — is a reasonable thing to discuss with your doctor, who may consider a repeat or a different assay in unusual circumstances.

Who should consider testing

Australian guidance recommends routine chlamydia testing for sexually active young people and for anyone with a new partner, a symptomatic presentation or a notified exposure.

If you are under 16, or if you need immediate treatment, contact-tracing support or a full sexual health assessment, a state-funded sexual health clinic is free, confidential and often better suited than a private test — they can test, treat and arrange partner notification on the spot, in the one visit.

• Sexually active people aged 15–29, at least once a year.
• Anyone with a new sexual partner or more than one partner in the past year.
• Men who have sex with men, more frequently and with site-specific testing.
• Anyone whose partner has been diagnosed with chlamydia or another STI.
• Anyone with discharge, pain on passing urine, pelvic or testicular pain, or bleeding between periods.
• People planning a pregnancy, and in antenatal care where risk factors are present.
• Anyone who wants reassurance after a specific unprotected exposure — bearing the window period in mind.

How testing works with FORM in Australia

You choose the test, we issue an Australian pathology request form, you attend an accredited collection centre for a urine sample or self-collected swab, and your result is delivered confidentially with a written explanation.

• No referral from your own GP is required. Privately requested pathology is arranged under a request from a registered medical practitioner working with our accredited lab partner.
• Collection is at Laverty (Healius) pathology centres Australia-wide (NATA / ISO 15189 accredited); swab options are self-collected in private.
• Hold urine for one to two hours before attending if you are giving a first-catch urine sample.
• Tell us which sites you need tested — urine or vaginal sampling alone does not cover rectal or throat infection.
• Results are confidential and delivered with a plain-English written explanation. Positive results are notified de-identified to the state or territory health department, as required by law of every Australian laboratory.
• FORM is a diagnostic testing service. We do not prescribe or supply antibiotics — a positive result must be taken to your GP or a sexual health clinic, who can also arrange confidential partner notification on your behalf.
• Australian ordering is currently pre-sale. Join the waitlist for launch notification; the price shown is indicative and will be confirmed at launch.